https://orcid.org/0000-0003-3340-7096
-
Views
-
Cite
Cite
Tomoko Yoshida, Tyler Alexander, Mengqi Xing, Sedigheh Mirzaei, AnnaLynn M Williams, Margaret Lubas, Tara M Brinkman, Wassim Chemaitilly, Leslie L Robison, Melissa M Hudson, Kevin R Krull, Angela Delaney, Hypogonadism and neurocognitive outcomes among childhood cancer survivors, European Journal of Endocrinology, Volume 190, Issue 3, March 2024, Pages 220–233, https://doi.org/10.1093/ejendo/lvae027
Close - Share Icon Share
Abstract
Childhood cancer survivors are at risk for hypogonadism. The impact of hypogonadism on neurocognitive impairment and emotional distress in the non-cancer population has been shown; however, the relationship among the childhood cancer survivor population is unknown. We aimed to evaluate the contribution of hypogonadism to neurocognitive impairment and emotional distress among survivors.
Cross-sectional study using retrospective cohort.
In total, 3628 survivors who completed standard neurocognitive tests (six domains: processing speed, memory, executive function, attention, academics, and global cognition) and self-reported emotional distress were included in our study. Participants were stratified by sex and gonadal status. Outcomes were compared between hypogonadal and eugonadal groups by multivariable analysis, adjusting for established predictors, and mediation analyses to determine the direct/indirect effects of hypogonadism on outcomes.
The hypogonadal group exhibited a higher prevalence of neurocognitive impairment across domains, but no difference in emotional distress. Hypogonadal females exhibited higher relative risk (1.7, 95% CI, 1.2–2.5) for impaired visual processing speed, compared to eugonadal females after adjusting for cancer-related variables. In mediation models, hypogonadism had a significant direct (P < .01) and indirect (from P < .01) impact on impairment in visual processing speed among females. Males demonstrated direct (P = .03) and indirect (P = .04) impact of hypogonadism on motor processing speed.
Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.
